Donald B Kyle

US Patent:

20200215052, Jul 9, 2020

Filed:

Jun 29, 2018

Appl. No.:

16/625011

Inventors:

- Stamford CT, US
Salvatore COLUCCI - Stamford CT, US
Stephen HARRIS - Weston CT, US
Michelle HUMMEL - Marlton NJ, US
Donald KYLE - Yardley PA, US
Garth WHITESIDE - Yardley PA, US

International Classification:

A61K 31/485
A61K 31/4468
A61K 9/00

Abstract:

The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g/mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g/mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.